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Abstract Photodynamic therapy uses nonthermal coher-
ent light delivered via ﬁber optic cable to locally activate a
photosensitive chemotherapeutic agent that ablates tumor
tissue. Owing to the limitations of light penetration, it is
unknown whether photodynamic therapy can treat large
osseous tumors. We determined whether photodynamic
therapy can induce necrosis in large osseous tumors, and if
so, to quantify the volume of treated tissue. In a pilot study
we treated seven dogs with spontaneous osteosarcomas of
the distal radius. Tumors were imaged with MRI before
and 48 hours after treatment, and the volumes of hypoin-
tense regions were compared. The treated limbs were
amputated immediately after imaging at 48 hours and
sectioned corresponding to the MR axial images. We
identiﬁed tumor necrosis histologically; the regions of
necrosis corresponded anatomically to hypointense tissue
on MRI. The mean volume of necrotic tissue seen on MRI
after photodynamic therapy was 21,305 mm
3 compared
with a pretreatment volume of 6108 mm
3. These pilot data
suggest photodynamic therapy penetrates relatively large
canine osseous tumors and may be a useful adjunct for
treatment of bone tumors.
Introduction
Photodynamic therapy (PDT) uses a nonthermal laser
delivered light through a ﬁber optic cable to stimulate a
photoactivated chemotherapeutic agent (photosensitizer)
that ablates tumor cells [10, 16, 17, 23, 26, 30, 33, 36].
PDT has limited systemic and local side effects [3, 32, 33].
Previous rodent studies suggest PDT can ablate various
forms of bone cancer [4, 5, 31, 37], although our concern
has been whether PDT can induce necrosis in larger
osseous tumors given presumed limitations of light pene-
tration in osseous tumors.
The purpose of this study was to determine if PDT could
induce necrosis in large osseous tumors and to quantify the
volume of tumor tissue ablated.
Materials and Methods
For this pilot study, we identiﬁed seven large-breed pet
dogs (33–65.5 kg) with spontaneous osteosarcomas in the
forelimb distal radius through the oncology clinic at the
University of California, Davis, School of Veterinary
Medicine. The radiographs and MR images of all the ani-
mals tested were consistent with osteosarcoma and later
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IIb [12, 13] and all of the tumors in the dogs except one had
areas of spontaneous necrosis present before therapy
identiﬁed on MRI (T1 gadolinium sequences). Consent for
treatment was obtained from the owners of the dogs. All
procedures were approved by the Animal Care Committee
at the University of California, Davis, School of Veterinary
Medicine.
The dogs were anesthetized and premedicated intrave-
nously using oxymorphone (0.05 mg/kg) and atropine
(0.2 mg/kg). Ketamine (5 mg/kg) and diazepam (0.25 mg/
kg) were used for induction. Anesthesia following endo-
tracheal intubation was maintained with isoﬂuorane and
oxygen. A pretreatment MRI (T1, T2, and T1 gadolinium)
of the affected limb was performed and the dogs then were
taken to the surgical suite where PDT was performed
(Fig. 1).
The affected limb was prepared and draped in sterile
fashion. A 2-mm stainless steel guide rod was placed
through a small stab incision over the proximal anterior
surface of the affected radius and advanced through the
intramedullary canal of the radius into the osteosarcoma
under ﬂuoroscopic guidance. A cannulated trochar was
placed over the guide rod and advanced to the center of the
tumor. The guide rod then was removed and a 0.94-mm
ﬁber optic cable was advanced through the guide rod and
placed in the tumor. The location of the cannulated trochar
and placement of the treatment ﬁber in the tumor were
conﬁrmed by intraoperative ﬂuoroscopy. The photosensi-
tizer verteporﬁn (benzoporphyrin derivative monoacid;
QLT, Inc, Vancouver, Canada) then was administered
systemically (0.4 mg/kg) through an intravenous access
portal over 10 minutes before light delivery. Light from a
690-nm diode laser was administered 5 minutes after
completion of the transfusion of the photosensitizer. Light
was delivered at 250 mW/cm over 1000 seconds through a
0.94-mm 9 5-cm cylindrical diffuser (Medlight SA,
Ecublens, Switzerland) for a total light dose of 500 J/cm.
One animal was used as a control in which light was
administered at 500 J/cm without administration of the
photosensitizer (sham treatment). The ﬁber optic cable was
removed after treatment. The animals were extubated and
monitored in the intensive care unit for 48 hours where
analgesia was maintained. Forty-eight hours posttreatment,
the animals returned to the MRI suite anesthetized and the
PDT-treated limbs were reimaged using the pretreatment
MRI protocol. Immediately after imaging, the animals
were taken to the procedure room and the affected fore-
limbs were amputated with wide margins, in conventional
fashion. The dogs were followed clinically in the oncology
unit postoperatively and received routine neoadjuvant
cisplatinum.
The forelimb of the dog was amputated and sectioned
from the wrist. Seventeen sections were cut in the axial
plane to correlate with alternate axial MR images based on
the distance from the distal radius. The specimens then
were decalciﬁed in 10% formic acid over 28 days and
sectioned using a microtome. The sections from each
amputated limb were ﬁxed on microscopy slides, stained
with hematoxylin and eosin, and analyzed under light
Fig. 1A–C (A) A lateral radio-
graph shows osteosarcoma of the
distal radius of the canine fore-
limb (*). (B) Fluoroscopy shows
placement of the ﬁber optic cable
(arrow) through the medullary
canal into the osteosarcoma. (C)
A photograph shows the affected
limb being treated with PDT.
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123microscopy by one of the authors (SB) and a dedicated
musculoskeletal pathologist (RK). Anatomic features of the
histology sections were used to conﬁrm the correlation
between MRI and histology sections. The tissue around the
ﬁber optic cable tract was assessed microscopically.
The area in the tumor with hypointense signal on before
and after PDT axial MRI sequences (T1 with gadolinium)
was measured and compared. The hypointense regions
signiﬁed avascular tissue [7, 19, 21]. The MR images of
each animal were reviewed independently by a musculo-
skeletal radiologist (CC). We measured the anteroposterior,
mediolateral, and rostrocaudal extent of hypointense tissue
in the tumor using a calibrated ruler in Merge eFilm
TM
(Milwaukee, WI) DICOM software. We then computed the
volume of the tumor tissue with hypointense signal using
Mimics
TM software (Materialise, Inc, Leuven, Belgium)
(Fig. 2). The volumetric assessment was calculated for
each treatment site by interpolating in the rostrocaudal
plane the area of hypointense signal on the axial MRI
through the software’s algorithm. We believed this to be a
more accurate representation of the effect of PDT versus
data given just for one representative region. The mean
volumes of tissue with hypointense signal were compared
before and posttreatment using a paired Student’s t test.
Finally, the pattern and distribution of hypointense sig-
nal seen on the axial MRI were compared with the
corresponding axial histology sections to assess whether
the pattern and distribution of hypointense tissue post-
treatment correlated with necrosis on histology. This was
performed by comparing anatomic features of the histology
sections to anatomic features of the MRI slices taken
equidistant from the wrist.
Results
PDT induced necrosis in all osteosarcomas treated
(Table 1; Fig. 3). The area of necrosis was easily seen on
gross sectioning. The tract of the ﬁber optic cable was
identiﬁed and the treated tumor and peripheral tissue were
examined in reference to this landmark. The hematoxylin
and eosin sections showed areas of extensive hemorrhagic
necrosis and cellular necrosis throughout the tumor around
the ﬁber tract. Regions of necrosis were characterized by
Fig. 2A–D (A) A preoperative
sagittal T1 gadolinium MR image
for Dog MQ shows the location of
the osteosarcoma affecting the
radius. (B) In a postoperative T1
gadolinium MR image, the hypo-
intense signal (circle) is seen 48
hours after PDT. (C) A pretreat-
ment axial section shows the size
and location of the osteosarcoma
compared with (D) a posttreat-
ment axial T1 gadolinium MR
image. The dimensions of the
hypointense signal before and
post-PDT were measured and
compared.
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123Table 1. Volume of necrosis in canine osteosarcomas after PDT
Canine Pre-PDT (mm
3) Post-PDT (mm
3) Anteroposterior (cm) Mediolateral (cm) Rostrocaudal (cm)
HR 1104 18,918 2.7 2.7 4.6
MQ 2 11,731 2.2 2.7 4
JR 988 7970 2.5 1.7 4.7
JF 4386 25,246 2.8 2.8 5.1
MG 637 28,027 2.2 2.8 4
BJ 29,534 35,941 2.5 2.7 9.2
Control 637 1913
Mean 6108* 21,305* 2.5 2.6 5.3
* A signiﬁcant effect was seen after treatment (p\0.003); PDT = photodynamic therapy.
Fig. 3A–F (A)A910 magniﬁ-
cation photomicrograph and (B)a
920 magniﬁcation photomicro-
graph of sections of treated
canine osteosarcoma show necro-
sis (Stain, hematoxylin and
eosin). (C) Blood pooling after
treatment was identiﬁed in sec-
tions in all animals treated except
for the control animal (Stain,
hematoxylin and eosin; original
magniﬁcation, 920). (D) A pho-
tomicrograph shows untreated
tumor tissue (Stain, hematoxylin
and eosin; original magniﬁcation,
920). (E) An axial T1 gadolinium
MR image shows the area of
hypointense tissue seen after
treatment. The regions from
which the histologic specimen
were obtained that are shown in
Illustrations A, B, and C are noted
by the arrows. (F) A preoperative
axial section of the same level
shows the original size and loca-
tion of the osteosarcoma affecting
the radius.
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123areas without cells with blood pooling and by regions with
necrotic cells, qualitatively characterized by loss of cellular
volume, hyperpigmentation, and increased nuclear density.
The latter was found toward the periphery of the treatment
site compared with the former found closer to the ﬁber tract
(Fig. 3). Bone necrosis, as seen by empty osteocyte lacu-
nae, also was evident in three of the dogs after PDT.
However, no structural damage to bone outside the ﬁber
tract was identiﬁed. In the control animal, blood pooling
occurred along the ﬁber tract but was conﬁned to the tract.
The tumor in the control dog had viable tumor cells without
evidence of necrosis adjacent to the ﬁber tract in contrast to
the treated tumors.
The mean volume of necrotic tissue seen on MRI after
PDT (21,305 mm
3) was larger (p\0.003) than the mean
pretreatment volume (6108 mm
3) (Table 1). The mean
anterior to posterior dimensions of the hypointense tissue
after PDT was 2.5 cm (range, 2.2–2.8 cm), the mean
medial to lateral dimension was 2.6 cm (range, 1.7–
2.8 cm), and the mean rostral to caudal dimension was
5.3 cm (range, 4–9.2 cm) (Table 1). The hypointense tis-
sue surrounding the treatment ﬁber tract seen on
posttreatment MRI was increased (p\0.003) compared
with pretreatment MRI except for the control (Fig. 4).
The distribution of hypointense signal seen on T1 gad-
olinium sequences matched the pattern and distribution of
necrosis seen on the corresponding histology sections
(Figs. 2, 3). Likewise, the axial dimension of hypointense
tissue on the control’s posttreatment MRI was minimal and
determined to be 3 mm, corresponding to the passage of
the cannula.
Discussion
PDT uses nonthermal coherent light delivered via ﬁber
optic cable to locally activate a photosensitive chemo-
therapeutic agent that ablates tumor tissue. It is unknown
whether PDT can treat large osseous tumors owing to the
limitations of light penetration. In this pilot study, we
determined if PDT can induce necrosis in large osseous
tumors and quantiﬁed the volume of treated tissue in seven
dogs with spontaneous osteosarcomas of the distal radius.
Osteosarcomas are common in dogs and commonly
affect the radius. The characteristics of canine osteosar-
comas are histologically similar to those of human
osteosarcomas and we therefore presumed this was a good
model to test our hypothesis. Limits to this study include
the limited number of dogs that were treated and the lim-
ited number of control animals. However, this was a pilot
study, and owing to ethical reasons, a limited number of
animals were used with limited followup (48 hours) before
amputation. The long-term clinical followup of the dogs
was not reported because the dogs were lost to followup
(\1 year), making it difﬁcult to determine whether the
treatment had either a positive or negative effect on
the dog’s survival. Likewise, a potential downside of the
technique used is potential seeding of tumor tissue into
adjacent tissue during placement and withdrawal of the
ﬁber optic cable and hemorrhage secondary to ﬁber
placement. Our assessments were not blinded, although we
did not believe this essential for this pilot study. Finally,
our study was limited in that there was variability in lesion
sizes produced in animals with the same type of tumor.
This can be explained in part by the following: the osteo-
sarcomas in this study were all Stage IIb and some dogs
had areas of spontaneous necrosis noted preoperatively.
Placement of ﬁbers in an area of preexisting necrosis
served to limit the measurable effect attributed to PDT and
skewed the results negatively. For example, the cylindrical
diffusing tip was placed in an area of preexisting necrosis
in the tumor of one animal (Dog JR, Table 1). The mea-
surable lesion in this animal’s osteosarcoma was limited on
the post-PDT MRI because the preexisting necrosis was
indiscernible in the mediolateral plane from the lesion
created from the PDT, rather than because there was a poor
response to treatment in that tumor. In contrast, in animals
in which there was no or limited spontaneous necrosis
preoperatively, large areas of necrosis from PDT treatment
were determined easily.
We observed necrosis histologically and on MRI.
Although necrosis was seen in all tumors except one before
PDT, the extent of necrosis after PDT was substantial in all
of the PDT-treated radii except for the control. The
hypointense tissue on MRI matched the area of necrosis
seen on histologic specimen, and we were able to obtain a
Fig. 4 A graph shows the effect of PDT on canine osteosarcomas.
The seven dogs with spontaneous forelimb osteosarcomas were
treated with PDT; one dog acted as a control (light only). Volumes of
necrosis seen on T1 gadolinium sequences were measured and
compared with the corresponding preoperative images. The mean
posttreatment volume was larger (p\0.003) than the pretreatment
volume.
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123volumetric measurement from the MRI to determine the
volume of necrosis after PDT was substantially increased.
The effect of PDT is mediated through direct ablation
and immune-mediated vascular stasis [11, 16]. We found a
mean treatment effect size of approximately 16 cm
3, with a
consistent effect seen in the anteroposterior (2.5 cm) and
mediolateral (2.6 cm) dimensions. The effect measured
along the rostrocaudal (5.2 cm) plane correlated well with
the length of the diffusing tip used for treatment in this
study (5 cm).
Our results are consistent with those of several trials in
rodents largely consisting of experiments in orthotopic
osteosarcoma, chondrosarcoma, and ﬁbrosarcoma models
[8, 14, 20, 28, 31]. In these studies, PDT was able to ablate
primary bone tumors, although the size of the tumors was
small. Several other animal studies showed PDT can
induce necrosis in metastatic adenocarcinomas in bone as
well [4, 6]. Burch et al. [4] showed, with a bioluminescent
metastatic rat model, PDT ablated human breast cancer in
the axial and appendicular skeleton. Several other early-
phase clinical trials have shown PDT is capable of ablating
various primary human cancers, including breast, prostate,
bladder, and lung cancer [2, 9, 10, 15, 17, 18, 24, 27, 29,
38]. However, the extent of ablation was limited in most of
these studies because the light source had to be placed on
the surface of the diseased tissue and not directly in the
tumor. In contrast, the ﬁber can be placed in the center of
the tumor in osseous tumors. It may be the skeleton is the
ideal place for PDT since the ﬁber optic cable can be
placed directly in the bone without compromising the
native tissue.
Our data show PDT can induce tumor necrosis in rela-
tively large bone tumors and the light penetration does not
appear to be a limiting factor in the animals treated. The
treatment protocol in our study used one 0.94-mm ﬁber.
However, the treatment effect could be increased by using
multiple ﬁbers placed accordingly. Arguably, complete
ablation of the osteosarcoma in a dog may have been
obtained if several ﬁbers were appropriately arranged in the
tumor in the medullary canal. The technique also is
applicable to the axial skeleton, and Burch et al. [5] also
examined safe application of low-dose PDT in porcine
vertebrae and canine vertebrae. The average volume of
necrosis in dogs in the current study is approximately the
size of large metastatic lesions seen in the thoracic and
lumbar spine [1, 11]. PDT may have potential as an
adjunctive therapy for treatment of spinal metastases along
with radiation and bisphosphonates [22, 25, 34, 35, 39].
Our pilot data suggest PDT can ablate a considerable
volume of large bone tumors and the light penetration in
osseous tumors is not a limiting factor. The other beneﬁts
of PDT are that it is minimally invasive (the treatment ﬁber
is less than 1 mm in diameter); because it is targeted, it has
limited systemic and local side effects and repeat treat-
ments can be made; the treatment time is, on average,
extremely short (33 minutes); and it could easily be used as
an adjunct with other strategies to treat osseous tumors.
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